Dan previously led portfolio strategy and planning for Genentech Research and Early Development (gRED), which delivered more than 80 drug candidates into development. He catalyzed gRED 2025, a strategy to propel Genentech research and development into the future. Dan helped shepherd the development and commercialization of immunotherapies ipilimumab and nivolumab at Medarex. Additionally, he worked as a Scientist at Exelixis and as a management consultant. Dan studied Molecular Biology and Public Policy at Princeton and received his PhD in Genetics at Harvard, and is also known for his work in the movement to end modern day slavery.